Tauziede-Espariat A, Simbozel M, Sievers P, Dangouloff-Ros V, Guida L, Blauwblomme T
Acta Neuropathol Commun. 2025; 13(1):8.
PMID: 39815333
PMC: 11737212.
DOI: 10.1186/s40478-024-01885-x.
Patel T, Singh G, Goswami P
J Med Life. 2024; 17(7):665-670.
PMID: 39440342
PMC: 11493159.
DOI: 10.25122/jml-2023-0515.
Blasco-Santana L, Colmenero I
Int J Mol Sci. 2024; 25(15).
PMID: 39126064
PMC: 11312892.
DOI: 10.3390/ijms25158498.
Gue R, Lakhani D
Biomedicines. 2024; 12(6).
PMID: 38927556
PMC: 11202067.
DOI: 10.3390/biomedicines12061349.
dAmati A, Bargiacchi L, Rossi S, Carai A, Bertero L, Barresi V
Front Mol Neurosci. 2024; 17:1268038.
PMID: 38544524
PMC: 10966132.
DOI: 10.3389/fnmol.2024.1268038.
Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.
Mishchenko T, Turubanova V, Gorshkova E, Krysko O, Vedunova M, Krysko D
Front Immunol. 2024; 14:1299064.
PMID: 38274827
PMC: 10809268.
DOI: 10.3389/fimmu.2023.1299064.
Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures.
Schoof M, Godbole S, Albert T, Dottermusch M, Walter C, Ballast A
Nat Commun. 2023; 14(1):7717.
PMID: 38001143
PMC: 10673884.
DOI: 10.1038/s41467-023-43564-w.
Refinement of diagnostic criteria for pediatric-type diffuse high-grade glioma, IDH- and H3-wildtype, MYCN-subtype including histopathology, TP53, MYCN and ID2 status.
Tauziede-Espariat A, Uro-Coste E, Nicaise Y, Sievers P, von Deimling A, Sahm F
Acta Neuropathol Commun. 2023; 11(1):170.
PMID: 37875973
PMC: 10594904.
DOI: 10.1186/s40478-023-01667-x.
Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity.
Bender K, Kahn J, Perez E, Ehret F, Roohani S, Capper D
Brain Tumor Pathol. 2023; 40(4):204-214.
PMID: 37561227
PMC: 10575802.
DOI: 10.1007/s10014-023-00468-3.
Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma.
Murdaugh R, Anastas J
Front Pharmacol. 2023; 14:1002296.
PMID: 37205910
PMC: 10191214.
DOI: 10.3389/fphar.2023.1002296.
Newly Recognized CNS Tumors in the 2021 World Health Organization Classification: Imaging Overview with Histopathologic and Genetic Correlation.
Rigsby R, Brahmbhatt P, Desai A, Bathla G, Ebner B, Gupta V
AJNR Am J Neuroradiol. 2023; 44(4):367-380.
PMID: 36997287
PMC: 10084895.
DOI: 10.3174/ajnr.A7827.
Adult-type and Pediatric-type Diffuse Gliomas : What the Neuroradiologist Should Know.
Nafe R, Porto L, Samp P, You S, Hattingen E
Clin Neuroradiol. 2023; 33(3):611-624.
PMID: 36941392
PMC: 10449995.
DOI: 10.1007/s00062-023-01277-z.
Pediatric high-grade glioma MYCN is frequently associated with Li-Fraumeni syndrome.
Guerrini-Rousseau L, Tauziede-Espariat A, Castel D, Rouleau E, Sievers P, Saffroy R
Acta Neuropathol Commun. 2023; 11(1):3.
PMID: 36609284
PMC: 9817308.
DOI: 10.1186/s40478-022-01490-w.
Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification.
Gianno F, Giovannoni I, Cafferata B, Diomedi-Camassei F, Minasi S, Barresi S
Pathologica. 2022; 114(6):422-435.
PMID: 36534421
PMC: 9763979.
DOI: 10.32074/1591-951X-830.
Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification.
Keck M, Sill M, Wittmann A, Joshi P, Stichel D, Beck P
Acta Neuropathol. 2022; 145(1):49-69.
PMID: 36437415
PMC: 9807491.
DOI: 10.1007/s00401-022-02516-2.
Changes to pediatric brain tumors in 2021 World Health Organization classification of tumors of the central nervous system.
Oztek M, Noda S, Romberg E, Cole B, Wright J, Ishak G
Pediatr Radiol. 2022; 53(3):523-543.
PMID: 36348014
DOI: 10.1007/s00247-022-05546-w.
2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist.
McNamara C, Mankad K, Thust S, Dixon L, Limback-Stanic C, DArco F
Neuroradiology. 2022; 64(10):1919-1950.
PMID: 35869291
DOI: 10.1007/s00234-022-03008-6.
Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series.
Buccoliero A, Giunti L, Moscardi S, Castiglione F, Provenzano A, Sardi I
Genes (Basel). 2022; 13(4).
PMID: 35456430
PMC: 9028123.
DOI: 10.3390/genes13040624.
EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression.
Antin C, Tauziede-Espariat A, Debily M, Castel D, Grill J, Pages M
Acta Neuropathol Commun. 2020; 8(1):183.
PMID: 33153494
PMC: 7643397.
DOI: 10.1186/s40478-020-01056-8.
The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts.
Tauziede-Espariat A, Debily M, Castel D, Grill J, Puget S, Roux A
Acta Neuropathol Commun. 2020; 8(1):104.
PMID: 32646492
PMC: 7346460.
DOI: 10.1186/s40478-020-00974-x.